达比加群酯用于儿童静脉血栓栓塞二级预防的安全性
这项开放标签、单臂、前瞻性队列3期安全性研究评估达比加群酯用于儿童继发性静脉血栓栓塞(VTE)预防的安全性。203例>3个月至<18岁儿童接受达比加群治疗,中位暴露36.3周;治疗期间VTE复发1.0%、大出血1.5%、无死亡,药代/药效关系与成人VTE患者相似,安全性良好。
要点
- 达比加群用于儿童VTE二级预防,治疗期间VTE复发率1.0%、大出血率1.5%。
- 203例儿童中84.2%用胶囊、15.8%用颗粒剂,中位暴露36.3周。
- 药代/药效关系与成人VTE患者相似,支持儿童剂量衔接。
核心结论
- 达比加群在>3个月至<18岁持续存在VTE危险因素的儿童中用于二级预防显示良好安全性。
研究设计与样本
- 开放标签、单臂、前瞻性队列3期安全性研究,纳入>3个月至<18岁儿童,按12至<18岁、2至<12岁、>3个月至<2岁分层。
- 入组儿童需经客观确诊VTE并接受标准治疗≥3个月,或已完成DIVERSITY试验(NCT01895777)达比加群或标准治疗且存在未解决的临床血栓危险因素需继续抗凝。
- 达比加群治疗最长12个月,危险因素消退可提前停药;共203例儿童接受治疗,中位暴露36.3周(范围0-57周)。
主要发现
- 治疗期间VTE复发2/203(1.0%),大出血3/203(1.5%),临床相关非大出血2/203(1.0%),轻微出血37/203(18.2%)。
- 治疗期间无死亡;在162例以深静脉血栓或中心静脉导管相关血栓为最近一次VTE的儿童中,治疗后血栓后综合征2/162(1.2%)。
- 达比加群的药代/药效关系与成人VTE患者相似。
关键数值与推荐
- 主要终点包括6个月和12个月时VTE复发、出血事件和死亡率。
- 203例中171例(84.2%)使用胶囊,32例(15.8%)使用颗粒剂。
临床怎么用
- 对于>3个月至<18岁、已完成初始抗凝且存在持续VTE危险因素的儿童,达比加群可作为二级预防的抗凝选择。
- 用药期间需关注出血事件,尤其是轻微出血(18.2%),并监测VTE复发。
局限性
- 单臂、开放标签设计,无对照组,安全性结果需谨慎解读。
- 样本量203例,各年龄层人数未报告,亚组结论受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to <18 years (age stratum 1), 2 to <12 years (stratum 2), and >3 months to <2 years (stratum 3) had an objectively confirmed diagnosis of VTE treated with standard of care (SOC) for ≥3 months, or had completed dabigatran or SOC treatment in the DIVERSITY trial (NCT01895777) and had an unresolved clinical thrombosis risk factor requiring further anticoagulation. Children received dabigatran for up to 12 months, or less if the identified VTE clinical risk factor resolved. Primary end points included VTE recurrence, bleeding events, and mortality at 6 and 12 months. Overall, 203 children received dabigatran, with median exposure being 36.3 weeks (range, 0-57 weeks); 171 of 203 (84.2%) and 32 of 203 (15.8%) took capsules and pellets, respectively. Overall, 2 of 203 children (1.0%) experienced on-treatment VTE recurrence, and 3 of 203 (1.5%) experienced major bleeding events, with 2 (1.0%) reporting clinically relevant nonmajor bleeding events, and 37 (18.2%) minor bleeding events. There were no on-treatment deaths. On-treatment postthrombotic syndrome was reported for 2 of 162 children (1.2%) who had deep vein thrombosis or central-line thrombosis as their most recent VTE. Pharmacokinetic/pharmacodynamic relationships of dabigatran were similar to those in adult VTE patients. In summary, dabigatran showed a favorable safety profile for secondary VTE prevention in children aged from >3 months to <18 years with persistent VTE risk factor(s). This trial was registered at www.clinicaltrials.gov as #NCT02197416.
引用
- Brandão LR, Albisetti M, Halton J, et al. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020. PMID: 31805182. doi:10.1182/blood.2019000998
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。